MAIA Biotechnology Inc. (MAIA)
AMEX: MAIA
· Real-Time Price · USD
2.02
0.06 (3.06%)
At close: May 09, 2025, 3:59 PM
2.00
-0.74%
After-hours: May 09, 2025, 07:50 PM EDT
Company Description
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer.
Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity.
The company was founded in 2018 and is headquartered in Chicago, Illinois.
MAIA Biotechnology Inc.
| Country | United States |
| IPO Date | Jul 28, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Dr. Vlad Vitoc M.B.A., M.D. |
Contact Details
Address: 444 West Lake Street Chicago, Illinois United States | |
| Website | https://www.MAIABiotech.com |
Stock Details
| Ticker Symbol | MAIA |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001878313 |
| CUSIP Number | 552641102 |
| ISIN Number | US5526411021 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vlad Vitoc M.B.A., M.D. | Co-Founder, President, Chief Executive Officer & Chairman of the Board of Directors |
| Dr. Sergei M. Gryaznov Ph.D. | Chief Scientific Officer |
| Jeffrey C. Himmelreich | Head of Finance and Principal Financial & Accounting Officer |
| Linda Moreira | Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 09, 2025 | 10-Q | Quarterly Report |
| May 06, 2025 | 8-K | Current Report |
| Apr 22, 2025 | 8-K | Current Report |
| Apr 08, 2025 | 4 | Filing |
| Apr 08, 2025 | 4 | Filing |
| Apr 08, 2025 | 4 | Filing |
| Apr 08, 2025 | 4 | Filing |
| Apr 08, 2025 | 4 | Filing |
| Apr 08, 2025 | 4 | Filing |
| Apr 08, 2025 | DEFA14A | Filing |